“We have filed our short-form prospectus, secured a lending partner in Australia and have grown our clinical trial revenue pipeline and related customer deposits, all of which will help us to fund our clinical trial and development work,” said Will Avery, CFO. “With these pieces in play we are excited for the growth we anticipate for PharmAla (MDXXF) in the year ahead.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXXF:
- Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial
- PharmAla Biotech Contracts UK CDMO for ALA-002 Manufacturing
- PharmAla contracts with UK-based CMO for ALA-002 manufacturing
- Psychedelic: Atai Beckley granted U.S. patent for EMP-01
- PharmAla Biotech Advances with Australian-Made MDMA Capsules